RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study |
|
|
| Recruiting | 3 | 12000 | Europe, Canada, Japan, US, RoW | RSVPreF3 OA vaccine | GlaxoSmithKline | Respiratory Syncytial Virus Infections | 09/26 | 09/26 | | |
